{
  "Clinical History Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        951, 
        974
      ]
    }
  ], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        839, 
        866
      ]
    }
  ], 
  "Laterality (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        869, 
        874
      ]
    }
  ], 
  "Macroscopic/Gross Description Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        489, 
        518
      ]
    }
  ], 
  "Microscopic Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1031, 
        1066
      ]
    }
  ], 
  "Nature of Specimen Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        796, 
        822
      ]
    }
  ], 
  "Neoplasm Behaviour (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        892, 
        900
      ]
    }
  ], 
  "Organ/Body Structure (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        875, 
        881
      ]
    }
  ], 
  "__text": "MSH|^~\\&|PATHLAB_LIS|HOSPITAL 1^9999^MOH|PIMS|CCO|20160503143316|38CE6ED8ACDB4C887D219DFDD297C66675DE5485|ORU^R01|Q1907576573T3579532223|P|2.5|\nPID|1||^^^^CMR^Ontario Remainder&9999&MOH~^^^^RMR^Ontario Remainder&9999&MOH~999999999^^^^MRN^HOSPITAL 1&9999&MOH||XXXXX^XXXXXXX^XXXXX||99999999|F||||||||||||||||||||||N|\nOBR|1|16:S3760|S-16-0018868|11529-5^Surgical Pathology Study Report^LN^P^Pathology^L|||20160429|||83097^XXXXXX^XXXXX||||||||||Y||20160503|||F|||||||99999^XXXXXX^XXXX|\n\n\n\n\n\n\n\nPath report.gross description\n\n\nThe following material is received in consultation from HOSPITAL \nO\nBlock x 1, labelled as 16:S3760 (A17) [internally labelled A1]\nH\\T\\E stained slide x 1, labelled as 16:S3760 (A17-1 L1)\nAlso received: correspondence, pathology report 16:S3760\n/sa 2016/04/29 12:40:25 EDT\n\n\nPath report.site of origin\n\n\nA Consult #\n\n\nPath report.final diagnosis\n\n\nRight breast tissue:\n- invasive mammary carcinoma present (See Synoptic Report)\n\n\nPath report.relevant Hx\n\n\nSee Correspondence - request for ER/PR and HER2/neu\n\n\nPath report.microscopic observation\n\nRepresentative section(s) from 1 block(s) of tumour are reviewed \nLocation of tumour: right breast \nHistologic Type(s): invasive adenocarcinoma \nImmunohistochemistry for estrogen receptor protein: Positive: moderate to strong nuclear staining in >90 % of invasive carcinoma \nImmunohistochemistry for progesterone receptor protein: Negative \nImmunohistochemistry for HER2/neu protein overexpression:  \n   SP3 - Negative (0) \n   A0485 - Negative (0) \n   Overall interpretation of HER2/neu protein overexpression: negative \n   Control comment: control slides stain appropriately \n \nImmunohistochemical methodology:  \n   ER/PR method:  \n      EP1 and PgR636 antibodies; EnVision Flex/Flex+ detection. \n      Positive if nuclear staining of any intensity in >1% of invading cells (Harvey et al, JCO 17;5, 1474-81, 1999) \n   HER2 method:  \n      A0485 and SP3 antibodies; EnVision Flex/Flex+ detection. \n      Positive if circumferential membrane staining that is complete, intense in > 10% of the invasive tumor cells (3+). \n      Equivocal if circumferential membrane staining that is incomplete and/or weak/moderate and within > 10% of the invasive tumor cells; OR \n      complete and circumferential membrane staining that is intense and within <= 10% of the invasive tumor cells (2+). (Wolff et al., J. Clin. Oncol. 2013; 31(31): 3997-4013). \n   Control comment: control slides stain appropriately\n\n\n"
}